Work productivity in rheumatoid arthritis patients from two Latin American countries treated with tofacitinib or biological DMARDs

Figures & data

Table 1. Baseline patient characteristics

		bDMARDs group	Tofacitinib group	p-Value
Number of subjects		70	100
Age – mean (SD)		51 (13)	55 (14)	0.072
Female – no. of patients (%)		65 (93)	85 (85)	0.11
Country – no. of patients (%)
Peru		45 (64)	39 (39)	0.002
Colombia		25 (36)	61 (61)
Area – no. of patients (%)
Rural		1 (1.4)	5 (5)	0.41
Urban		69 (99)	95 (95)
Access to RA treatment
Access mechanism – no. of patients (%)
Complementary		1 (1.4)	2 (2)	<0.001
Patient		1 (1.4)	10 (10)
Private		24 (34)	67 (67)
Public		41 (59)	12 (12)
No report		3 (4.3)	9 (9%)
Access limitation – no. of patients (%)		10 (14)	29 (2)	0.024
No report – no. of patients (%)		3 (4.3)	9 (9)
Time to supply (days) – mean (SD)		24 (31)	22 (45)	0.0017
Duration of RA (years) – mean (SD)		6 (6.8)	6.5 (7.2)	0.81
Time previous treatment – mean (SD)		34 (37)	26 (31)	0.091
Concomitant therapy – no. of patients (%)
Leflunomide		20 (29)	15 (15)	0.05
Methotrexate		30 (56)	52 (52)	0.75
Aminoquinolines		7 (10)	16 (16)	0.37
Corticosteroids		60 (86)	77 (77)	0.22
Activity of disease
RAPID3 score		5.94 (1.62)	5.88 (1.99)	0.83
DAS28 score		5.88 (4.46)	5.21 (1.01)	0.22
HAQ score		1.45 (0.60)	1.61 (0.75)	0.13
EQ5D score		0.22 (0.29)	0.30 (0.32)	0.08

bDMARDs, biological disease-modifying antirheumatic drugs; DAS28, Disease Activity Score including a 28-joint count; EQ5D, EuroQol Five-Dimensional questionnaire; HAQ-DI, Health Assessment Questionnaire-Disability Index; RAPID3, Routine Assessment of Patient Index Data 3; SD, standard deviation.

Figure 1. Baseline employment status of the patients.

Table 2. WPAI outcomes: Change from baseline at month 6 according to work status

	Employee	Nonemployee	p-Value
Number of subjects	56	113
Age – mean (SD)	49.1 (11.6)	55.6 (14.3)	0.002
Female – no. of patients (%)	50 (89.3)	99 (87.6)	1.00
Country – no. of patients (%)
Peru	25 (44.6)	59 (52.2)	0.41
Colombia	31 (55.4)	54 (47.8)
Area – no. of patients (%)
Rural	0 (0.0)	6 (5.31)	0.18
Urban	56 (100)	107 (94.7)
Access to RA treatment
Access mechanism – no. of patients (%)			0.17
Complementary	2 (3.57)	1 (0.89)
Patient	4 (7.14)	7 (6.19)
Private	35 (62.5)	55 (48.7)
Public	13 (23.2)	40 (35.4)
No report	2 (4.76)	8 (11.3)
Access limitation – no. of patients (%)	12 (21.4)	26 (23.0)	0.84
No report – no. of patients (%)	2 (3.6)	10 (8.9%)
Time to supply (days) – mean (SD)	20.6 (40.0)	24.2 (38.5)	0.60
Duration of RA (years) – mean (SD)	7.12 (8.2)	5.9 (6.4)	0.33
Time previous treatment – mean (SD)	21.6 (22.4)	33.0 (37.9)	0.16
Concomitant therapy – no. of patients (%)
Leflunomide	15 (26.8%)	18 (15.9%)	0.10
Methotrexate	31 (55.4%)	68 (60.2%)	0.62
Aminoquinolines	9 (16.1%)	13 (11.5%)	0.47
Corticosteroids	47 (83.9%)	89 (78.8%)	0.54
Activity of disease
RAPID3 score	5.38 (2.01)	6.17 (1.70)	0.013
DAS28 score	5.82 (5.00)	5.31 (0.971)	0.454
HAQ score	1.48 (0.71)	1.58 (0.69)	0.356
EQ5D score	0.33 (0.33)	0.23 (0.30)	0.049

bDMARDs, biological disease-modifying antirheumatic drugs; DAS28, Disease Activity Score including a 28-joint count; EQ5D, EuroQol Five-Dimensional questionnaire; HAQ-DI, Health Assessment Questionnaire-Disability Index; RAPID3, Routine Assessment of Patient Index Data 3; RA, rheumatoid arthritis; SD, standard deviation.

Table 4. Lost days per year due to absenteeism and presenteeism by studied groups

	bDMARDs group	Tofacitinib group
Absenteeism
Baseline – mean (SE)	90.37 (16.82)	78.72 (18.68)
Follow-up at 6 month – mean (SE)	27.10 (13.67)	21.94 (13.18)
Presenteeism
Baseline – mean (SE)	148.08 (15.06)	141.07 (15.55)
Follow-up at 6 month – mean (SE)	69.32 (15.16)	58.33 (10.92)

bDMARDs, biological disease-modifying antirheumatic drugs; SE, standard error.

Table 3. WPAI outcomes: Change from baseline at month 6 for each group

	bDMARDs group	Tofacitinib group	p-Value
Patients working for pay at baseline (n)	28	28
Patients with absenteeism reported at both visits (n)	22	22
Patients with presenteeism/productivity loss reported at both visits (n)	21	23
Absenteeism
Unadjusted least square – mean (SE)	−24.2 (7.02)	−22.4 (7.02)	0.858
Adjusted least square – mean (SE)	−19.4 (7.99)	−18.3 (7.74)	0.912
Presenteeism
Unadjusted least square – mean (SE)	−34.8 (6.16)	−34.8 (5.89)	0.998
Adjusted least square – mean (SE)	−34.8 (6.16)	−34.8 (5.89)	0.998
Productivity loss
Unadjusted least square – mean (SE)	−39.2 (6.79)	−36.9 (6.47)	0.806
Adjusted least square – mean (SE)	−7.4 (15.6)	−3.9 (16.5)	0.701
Activity impairment
Unadjusted least square – mean (SE)	−38.4 (3.66)	−32.8 (3.18)	0.246
Adjusted least square – mean (SE)	−49.90(13.30)	−43.8 (11.00)	0.536

bDMARDs, biological disease-modifying antirheumatic drugs; SE, standard error; n, number of patients.

Figure 2. Unadjusted WPAI measures estimated at baseline and 6-month (± 1 month) follow-up. (a) Absenteeism and presenteeism. (b) Productivity loss and activity loss. The change from baseline at month 6and the p-value are above the bars.